Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336382 · ClinicalTrials.gov registry record
Tau Biomarkers in Late-onset Psychosis (LOP)
A clinical trial of Late Onset Schizophrenia and Delusional Disorder (Late Onset), sponsored by Jeremy Koppel.
- Recruiting
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT06336382: Recruiting study of Late Onset Schizophrenia and Delusional Disorder (Late Onset), sponsored by Jeremy Koppel.
NCT06336382 is a study of Late Onset Schizophrenia and Delusional Disorder (Late Onset) that is actively recruiting participants, run by Jeremy Koppel. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06336382, a study of Late Onset Schizophrenia and Delusional Disorder (Late Onset), is actively recruiting participants, sponsored by Jeremy Koppel.
- RECRUITING
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.
Primary Outcome
To determine whether there are increases in tau pathology in those with psychotic episodes that occur late in life employing tau PET ligands, and whether those increases are etiologic contributors to a stable psychosis or are a presage of an incipient cognitive decline.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Tau PET imaging scan
Study Locations (1)
New York
- The Feinstein Institutes for Medical Research - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2027-06-30 |
What NCT06336382 shows while recruiting
NCT06336382 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 2 conditions, with Late Onset Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Tau PET imaging scan is the first listed.
NCT06336382 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06336382 about?
NCT06336382 is a clinical study titled "Tau Biomarkers in Late-onset Psychosis (LOP)". Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as n...
What is the current status of trial NCT06336382?
This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2024-02-16. Estimated completion is 2027-06-30.
What conditions does trial NCT06336382 study?
This clinical trial studies the following conditions: Late Onset Schizophrenia, Delusional Disorder (Late Onset).
What interventions are being tested in trial NCT06336382?
The interventions under investigation include: Tau PET imaging scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06336382?
This trial is sponsored by Jeremy Koppel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06336382 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI